» Articles » PMID: 11496233

Immunostimulatory Sequence DNA Linked to the Amb a 1 Allergen Promotes T(H)1 Cytokine Expression While Downregulating T(H)2 Cytokine Expression in PBMCs from Human Patients with Ragweed Allergy

Overview
Date 2001 Aug 10
PMID 11496233
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies have demonstrated that bacterially derived immunostimulatory sequences (ISSs) of DNA can activate the mammalian innate immune system and promote the development of T(H)1 cells. Promotion of T(H)1 immunity by means of immunotherapy in allergic patients has led to the alleviation of symptoms that result from allergen-specific T(H)2 responses.

Objective: Our purpose was to investigate whether the T(H)1-enhancing properties of ISSs could be used to alter the T(H)2-dominated immune response of allergic PBMCs in vitro.

Methods: Ragweed protein-linked ISS (PLI) was generated from a specific, highly active 22-base ISS and Amb a 1, the immunodominant allergen in ragweed pollen, to combine the T(H)1-enhancing properties of ISSs with allergen selectivity, and its activity was investigated in PBMC cultures from subjects with ragweed allergy.

Results: PLI was markedly successful at reversing the dominant allergen-induced T(H)2 profile while greatly enhancing IFN-gamma production. Delivering ISSs in a linked form proved to be much more effective at modulating the resulting cytokine profile than delivering free ISSs in a mixture with unlinked Amb a 1. PLI also demonstrated cytokine-modulating properties, even when used to stimulate cells that had already been primed for 6 days with Amb a 1. The antigen specificity of the action of PLI was confirmed by the observations that PLI enhances Amb a 1--specific T-cell proliferation.

Conclusion: These data indicate that delivery of ISSs within an antigen-specific context exhibits potent cytokine-modulating activity and, combined with its reduced allergenicity, makes this molecule a strong candidate for use in improved immunotherapy applications.

Citing Articles

Novel adjuvants in allergen-specific immunotherapy: where do we stand?.

Lin Y, Zimmermann J, Schulke S Front Immunol. 2024; 15:1348305.

PMID: 38464539 PMC: 10920236. DOI: 10.3389/fimmu.2024.1348305.


Past, present, and future of allergen immunotherapy vaccines.

Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke-Tejkl M, Flicker S, Kudlay D Allergy. 2020; 76(1):131-149.

PMID: 32249442 PMC: 7818275. DOI: 10.1111/all.14300.


Induction of Interleukin-10 Producing Dendritic Cells As a Tool to Suppress Allergen-Specific T Helper 2 Responses.

Schulke S Front Immunol. 2018; 9:455.

PMID: 29616018 PMC: 5867300. DOI: 10.3389/fimmu.2018.00455.


The dichotomy of pathogens and allergens in vaccination approaches.

Baird F, Lopata A Front Microbiol. 2014; 5:365.

PMID: 25076945 PMC: 4100532. DOI: 10.3389/fmicb.2014.00365.


Vaccine adjuvants: mode of action.

De Gregorio E, Caproni E, Ulmer J Front Immunol. 2013; 4:214.

PMID: 23914187 PMC: 3728558. DOI: 10.3389/fimmu.2013.00214.